多西他赛联合顺铂治疗晚期非小细胞肺癌43例

目的:观察国产多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应。方法:不能手术的Ⅲ、Ⅳ期非小细胞肺癌病人43例。d 1多西他赛75 mg·m~(-2),顺铂70～75 mg·m~(-2),21 d为一个周期,每2个周期评价疗效,共完成4个周期。结果:43例病人共完成165个周期化疗,均可评价疗效,完全缓解(CR)1例,部分缓解(PR)13例,微效(MR)7倒,疾病稳定(SD)13例,疾病进展(PD)9例,总有效率(RR)49％,临床获益率79％,中位生存期(MST)是10．7 mo,疾病进展时间(TTP)是7．2 mo,1年生存率是39％。主要不良反应是白细胞下降、消化道反应、乏力、脱发。结论:多西他赛联合顺铂治疗晚期非小细胞肺癌疗效确切,耐受良好。

Combination of docetaxel and cisplatin in treatment of 43 patients with advanced non-small cell lung cancer

AIM:To investigate the antitumor effect and the adverse events of combination chemotherapy of cisplatin and docetaxel made in China in advanced non-small cell lung cancer(NSCLC).METHODS:Forty- three patients with advanced NSCLC of stageⅢtoⅣwho were unable to undergo the operation were selected and treated with docetaxel of 75 mg·m~(-2)and cisplatin 70-75 mg·m~(-2)on the first day of a 21 d cycle.Each patient completed 4 cycles,and the antitumor effects were observed every 2 cycles.RESULTS:All the patients completed 165 cycles.The number of patients who showed complete response,partial response, minimal response,stable disease,and progressive disease was 1,13,7,13,and 9,respectively.The response rate was 49%,and clinical benefit rate was 79%.The median survival time(MST)was 10.7 mo and time to progress(TTP)was 7.2 mo.The survival rate of 1 a was 39%.The common adverse events were leukopenia,gastrointestinal symptoms,fatigue,and alopecia.CONCLUSION:The combination chemotherapy is effective and tolerable in patients with advanced NSCLC.